The MCAZ posted a letter to Twitter July 26 informing all licensed cannabis/hemp producers, manufacturers, importers/exporters and retail pharmacists that the organization is now accepting and reviewing applications for the approval of selling hemp-based CBD products as complementary medicines to patients, under certain conditions, Bloomberg reported.

Some conditions include submitting product samples and a certificate of analysis, stating the indications, warning and contraindications, and more.

The MCAZ stated at the end of the letter, “Any hemp-based CBD product applications that do not meet the criteria above may not be approved for distribution and will be confiscated. Further, sellers may be prosecuted for selling unapproved complementary medicines.”